Se connecter

Bibliographies thématiques / DRUG DESIGNING / Livres

Livres sur le sujet « DRUG DESIGNING »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : DRUG DESIGNING.

Auteur : Grafiati

Publié le 11 septembre 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs livres pour votre recherche sur le sujet « DRUG DESIGNING ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les livres sur diverses disciplines et organisez correctement votre bibliographie.

1

Kinam, Park, et Mrsny Randy J. 1955-, dir. Controlled drug delivery : Designing technologies for the future. Washington, D.C : American Chemical Society, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Evans, David G. Designing an effective drug-free workplace compliance program. Deerfield, IL : Clark Boardman Callaghan, 1993.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Mayforth, Ruth D. Designing antibodies. San Diego : Academic Press, Inc., 1993.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

R, Antos Joseph, Spoor Christian et United States. Congressional Budget Office., dir. Issues in designing a prescription drug benefit for Medicare. [Washington, D.C.] : Congress of the United States, Congressional Budget Office, 2002.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

1942-, Ellickson Phyllis L., dir. Designing and implementing Project ALERT : A smoking and drug prevention experiment. Santa Monica, CA : RAND, 1988.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Loomis, Lloyd. Drug testing : A workplace guide to designing practical policies and winning arbitrations. Washington, D.C : Bureau of National Affairs, 1990.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Center, Joslin Diabetes, dir. Joslin's insulin deskbook : Designing and initiating insulin treatment programs. Boston, MA : Joslin Diabetes Center, c2008., 2008.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Rahrer, J. Stuart. Preparing for tomorrow-- today : Designing a personalized plan to prevent your child's alcohol-drug abuse. Fort Wayne, IN : Pharos Consulting & Publications, 1997.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Barbara, Davis. Peer support : Designing interpersonal skills training plan. [Edmonton] : Alberta Alcohol and Drug Abuse Commission, 1989.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

March, Darren. Designing new antiviral drugs for AIDS : HIV-1 protease and its inhibitors. Austin : R.G. Landes, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Morphy, J. Richard, et C. John Harris, dir. Designing Multi-Target Drugs. Cambridge : Royal Society of Chemistry, 2012. http://dx.doi.org/10.1039/9781849734912.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Designing a twenty-first century Medicare prescription drug benefit : Hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eighth Congress, first session, April 8, 2003. Washington : U.S. G.P.O., 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

13

1936-, Martin Yvonne Connolly, et Willett Peter 1953-, dir. Designing bioactive molecules : Three-dimensional techniques and applications. Washington, DC : American Chemical Society, 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

14

1964-, Kimko Hui C., et Duffull Stephen B. 1964-, dir. Simulation for designing clinical trials : A pharmacokinetic-pharmacodynamic modeling perspective. New York : Marcel Dekker, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Barger, Raymond L. A method for designing blended wing-body configurations for low wave drag. [Washington, DC] : National Aeronautics and Space Administration, Office of Management, Scientific and Technical Information Program, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

16

Dashora, Kamlesh. Drug Designing. Discovery Publishing House Pvt Ltd, 2016.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

Kothekar, V. Essentials of Drug Designing. Dhruv Publications, 2005.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Designing Multi-Target Drugs. Royal Society of Chemistry, The, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

19

Designing Hydrogels for Controlled Drug Delivery. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03928-357-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Sharma, Anju, Rajnish Kumar et Rajesh Kumar Tiwari. Introduction to Drug Designing and Development. Nova Science Publishers, Incorporated, 2014.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

22

Mani, Ashutosh. Recent Advances in Computer Aided Drug Designing. Nova Science Publishers, Incorporated, 2021.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Gupta, Sikha. Insilico Screning & Drug Designing For Lipoic Acid-B Protein. LAP Lambert Academic Publishing, 2012.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Antos, Joseph. Issues in Designing a Prescription Drug Benefit for Medicare. Diane Pub Co, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

(Editor), Kinam Park, et Randall J. Mrsny (Editor), dir. Controlled Drug Delivery : Designing Technologies for the Future (Acs Symposium Series). An American Chemical Society Publication, 2000.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Jojarth, Christine. Crime, War, and Global Trafficking : Designing International Cooperation. Cambridge University Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Jojarth, Christine. Crime, War, and Global Trafficking : Designing International Cooperation. Cambridge University Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Jojarth, Christine. Crime, War, and Global Trafficking : Designing International Cooperation. Cambridge University Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Jojarth, Christine. Crime, War, and Global Trafficking : Designing International Cooperation. Cambridge University Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Jojarth, Christine. Crime, War, and Global Trafficking : Designing International Cooperation. Cambridge University Press, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

A Practical Guide To Designing Phase Ii Trials In Oncology. John Wiley & Sons Inc, 2014.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Designing Alcohol and Other Drug Prevention Programs in higher education : Bringing theory into practice. Newton, Mass : U.S. Dept. of Education, Office of Educational Research and Improvement, Educational Resources Information Center, 1997.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

O'Quigley, John, Alexia Iasonos et Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

O'Quigley, John, Alexia Iasonos et Björn Bornkamp. Handbook of Methods for Designing Monitoring and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2019.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

O'Quigley, John, Alexia Iasonos et Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

O'Quigley, John, Alexia Iasonos et Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

37

Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

38

Bilirakis, Michael. Designing a Twenty-first Century Medicare Prescription Drug Benefit : Hearing Before the Comm. on Energy And Commerce, U.s. House of Representatives. Diane Pub Co, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

US GOVERNMENT. Designing a Twenty-First Century Medicare Prescription Drug Benefit : Hearing Before the Subcommittee on Health of the Committee on Energy and Commerce. Government Printing Office, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

40

National Aeronautics and Space Administration (NASA) Staff. Method for Designing Blended Wing-Body Configurations for Low Wave Drag. Independently Published, 2018.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

(Editor), M. G. Ford, et European Symposium on Quantitative Structure-Activity Relationships 20 (Editor), dir. Euroqsar 2002 Designing Drugs and Crop Protectants : Processes, Problems and Solutions. Blackwell Publishers, 2003.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

42

O'Quigley, John, Alexia Iasonos et Bjö Bornkamp. Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Taylor & Francis Group, 2017.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

43

Designing Bioactive Molecules : Three-Dimensional Techniques and Applications (Computer Applications in Chemistry Collection). An American Chemical Society Publication, 1998.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

44

Sjøgren, Per, Frank Elsner et Stein Kaasa. Non-opioid analgesics. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0096.

Texte intégral

Résumé :

Non-opioid analgesics encompass the non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). The NSAIDs include acetylsalicylic acid (ASA, aspirin), dipyrone (metamizole), and numerous other drugs in diverse classes. The NSAIDs have potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. In palliative medicine, they represent the first step of the World Health Organization’s analgesic ladder used for mild pain and they are an important supplement to opioids and adjuvant drugs at higher steps of the ladder. The disadvantages of non-opioid analgesics include a ceiling effect for pain relief and the risk of side effects. NSAIDs are also associated with an increased risk of adverse gastrointestinal, renal, and cardiovascular effects and hepatotoxicity can result from overdosing with paracetamol. This chapter describes the clinical pharmacology of NSAIDs, their classification, molecular mechanisms of action and adverse effects, as well as some recent developments aimed at designing effective anti-inflammatory agents with improved safety and tolerability profiles.

Styles APA, Harvard, Vancouver, ISO, etc.

45

Ray, Sumantra (Shumone), Sue Fitzpatrick, Rajna Golubic, Susan Fisher et Sarah Gibbings, dir. Clinical trial design. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199608478.003.0014.

Texte intégral

Résumé :

This chapter outlines the various study designs and their uses. The phases of drug development are described and the appropriate study design employed at each phase of development is identified Elimination of bias is critical to the study design and methods of eliminating bias are discussed, defining the population, randomisation and blinding. A summary of the elements to be considered when designing a study are presented including the types of control, placebo or active, and their uses, Non comparative and comparative designs are presented. In the comparative design both within and between patient designs are discussed including crossover, parallel, sequential, factorial and left right comparisons. Patient outcomes measures as well as efficacy measurement are required for new treatments. There is a brief review of pharmaeconomic study designs. Other types of study design, dose escalation and dose response studies are also discussed. As well as reducing bias in studies another critical element is the recording of the primary assessment methods. The choice of methods will affect other aspects of the study such as the statistical considerations. The methodology must be standardised and validated.

Styles APA, Harvard, Vancouver, ISO, etc.

46

Wohlbier, Thomas. Nanohybrids. Materials Research Forum LLC, 2021. http://dx.doi.org/10.21741/9781644901076.

Texte intégral

Résumé :

The book covers preparation, designing and utilization of nanohybrid materials for biomedical applications. These materials can improve the effectiveness of drugs, promote high cell growth in new scaffolds, and lead to biodegradable surgical sutures. The use of hybrid magneto-plasmonic nanoparticles may lead to non-invasive therapies. The most promising materials are based on silica nanostructures, polymers, bioresorbable metals, liposomes, biopolymeric electrospun nanofibers, graphene, and gelatin. Much research focuses on the development of biomaterials for cell regeneration and wound healing applications.

Styles APA, Harvard, Vancouver, ISO, etc.

47

Simulation for Designing Clinical Trials : A Pharmacokinetic-Pharmacodynamic Modeling Perspective (Drugs and the Pharmaceutical Sciences, Vol 127) (Drugs and the Pharmaceutical Sciences). Informa Healthcare, 2002.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Mills, Gary H. Under-representation of older people in clinical trials. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689644.003.0016.

Texte intégral

Résumé :

Key points• Older people, often with high levels of co-morbidity and polypharmacy, are increasing in number as the population ages.• Study populations in clinical trials have often not mirrored the population that will consume the drugs or treatments being investigated.• Regulators, ethics committees, and funding bodies must recognize the need for inclusion of older people and the complexities this imposes on investigators.• Across all aspects of medicine, funding for research into how best to safely include older people in clinical trials is vital.• Researchers should not be disadvantaged by designing studies to meet the needs of the age range of patients expected to receive the treatment being investigated; this should include provision for older people.

Styles APA, Harvard, Vancouver, ISO, etc.

49

Grant, Robert. Tumours of the brain and skull. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569381.003.0624.

Texte intégral

Résumé :

Over the last 10 years, there have been several important advances in cell biology, molecular genetics, and targeted therapies in neuro-oncology. Improved neurosurgical techniques such as frameless stereotaxy, awake craniotomy, and intra-operative MRI, safer methods of directing radiotherapy, new chemotherapy approaches, and novel modalities of therapy provide optimism that there will eventually be some improvements in treatment-related morbidity and survival. There has also been an increasing change from individual clinician decision making to decision making by multidisciplinary teams of neurosurgeons, neurologists, clinical oncologists, neuropathologists, neuroradiologists, and specialist nurses with the aim of improving decision making, management planning across specialties, communication, and enrolment in suitable clinical trials. In addition, Good Clinical Practice guidelines, an international ethical and scientific quality standard for designing, conducting, recording, and reporting trials, increases the onus and responsibilities on clinical investigators to perform trials to the highest standard and to have the trials externally monitored, and the trial conduct and results audited. While these obligatory and statutory responsibilities are labour intensive and time consuming, they should improve the quality of trials by limiting the possibility of unintentional bias or fraud. Improving the recording of serious adverse event reporting through trial quality assurance and quality control procedures will help ensure that a balanced view of the effects of a drug or procedure is identified earlier than in the past. It will be interesting to see how research develops over the next decade.

Styles APA, Harvard, Vancouver, ISO, etc.

50

Knaggs, Roger D. The molecular structure of the μ‎-opioid receptor. Sous la direction de Paul Farquhar-Smith, Pierre Beaulieu et Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0038.

Texte intégral

Résumé :

The landmark paper discussed in this chapter describes the crystal structure of the μ‎-opioid receptor (also known as MOP-1). Opioids are some of the oldest known drugs and have been used for over 4,000 years; however, in addition to having beneficial analgesic effects, they are associated with a myriad of side effects that can minimize their use. Although the gene sequences of the opioid receptors were determined in the 1990s it has taken much longer to translate this into visualizing their three-dimensional structure. The μ‎-opioid receptor consists of seven transmembrane α‎-helices that are connected by three extracellular loops and three intracellular loops, with a wide open binding pocket which offers many potential ligand interaction sites, and evidence of dimerization. Understanding the crystal structure of the μ‎-opioid receptor in much more detail aids explanation of the molecular determinants of ligand recognition and selectivity and will be of use in designing novel opioids with improved efficacy and fewer side effects.

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!